Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2005

01-03-2005

Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of β-catenin

Authors: Xiao-Xin Cheng, Zi-Chuang Wang, Xiao-Yan Chen, Yuan Sun, Qing-You Kong, Jia Liu, Xue Gao, Hong-Wei Guan, Hong Li

Published in: Clinical & Experimental Metastasis | Issue 1/2005

Login to get access
Metadata
Title
Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of β-catenin
Authors
Xiao-Xin Cheng
Zi-Chuang Wang
Xiao-Yan Chen
Yuan Sun
Qing-You Kong
Jia Liu
Xue Gao
Hong-Wei Guan
Hong Li
Publication date
01-03-2005
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2005
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-005-4578-8

Other articles of this Issue 1/2005

Clinical & Experimental Metastasis 1/2005 Go to the issue

OriginalPaper

Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis

OriginalPaper

Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior

OriginalPaper

Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells

OriginalPaper

Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats

OriginalPaper

Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow

OriginalPaper

Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits